In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...
Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics for a whopping $1 billion upfront. The deal – which has a potential total ...
Investing.com - Canada’s main stock index slipped on Tuesday as well, a day after the average retreated from some of its November gains. The S&P/TSX Composite index was down 0.17% or 52... Gold prices ...
Bitcoin price today: retreats to $95k as rate fears wipe out recent rebound By Investing.com - Jan 08, 2025 4 Investing.com-- Bitcoin retreated on Wednesday, extending overnight losses and wiping out ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback